Design Pharma is changing the current paradigms of GPCR drug discovery with a more than 100-fold deeper exploration of drug libraries compared to the industry standard and higher quality data based on readout of drug target activity, not just affinity or in silico: 1. high quality hit candidates - assays at all throughput levels test drug activity, not just affinity, 2. for the first time, we will screen the largest libraries for drug activity, 3. drug activity screens at tremendous speed - orders of magnitude higher assay throughput than the industry standard, 4. accessible to all modalities (biologics, small molecules, peptides, DEL). Our platform is based on NGS-assisted multiplex GPCR screening, where more than 300 GPCRs per assay are tested simultaneously to assess dose-response and selectivity of ligands at once. Multiplexing GPCRs enables powerful data generation for computational and experimental drug development. This unprecedented scale enables powerful data generation for drug development using design, build, test, and learn cycles and provides an exceptional opportunity to create a proprietary cheminformatics database for identifying hits and ML approaches. We will further transform GPCR drug discovery with new screening platforms in emulsion/droplet formats for ultra-scale functional GPCR screening of live cells in millions of parallel droplet incubators, replacing traditional multi-well technologies. Join us to develop breakthrough therapeutics. Working together - winning together.